Jefferies' Aveo Pharmaceuticals Management Remains Confident in Differentiation From Inlyta

Jefferies published a research report concerning Aveo Pharmaceuticals AVEO recent management meeting. In the report, Jefferies states, “We had the opportunity to meet with AVEO management for an update on their thoughts post-release of top-line TIVO-1 results. We continue to believe that the 12-month progression free survival (PFS) and superior side effect profile will make tivo the new standard of care for renal cell carcinoma (RCC).” Jefferies maintains its Buy rating and $30 PT on Aveo Pharmaceuticals, which closed Friday at $14.83.